Integrating Bio-metabolism and Structural Changes for the Diagnosis of Dementia
Publisher
Springer Singapore
Reference21 articles.
1. Abbott A. A problem for our age. Nature. 2011;475:S2–4. 2. Servigny J, Bussière PCT, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O’Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rodes K, Ferrero J, Hang Y, Milulskis A, Grimm J, Hock C, Mitsch RM, Sandrock A. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537:50–6. 3. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Alsen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9:119–28. 4. Sokoloff L, Reivichl M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M. The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedures, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28:897–916. 5. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and pittsburgh compound-B. J Cereb Blood Flow Metab. 2005;25:1528–47.
|
|